Zoetis Inc. (ZTS) experienced a sharp stock decline on Wednesday after the animal health company slashed its full-year 2026 revenue and profit outlook, following a first-quarter earnings miss driven by a slowdown in the U.S. pet-care market. Shares fell $23.86, or 21.5%, to close at $87.31, reducing its market capitalization to roughly $36.9 billion.
Q1 Results Fall Short
For the first quarter ended March 31, 2026, Zoetis reported adjusted earnings per share (EPS) of $1.53, missing the consensus estimate of $1.61 compiled by LSEG. Revenue came in at $2.3 billion, a 3% increase year-over-year but slightly below the $2.31 billion expected by analysts. Net income was $601 million, or $1.42 per diluted share.
The company's U.S. companion-animal segment, which includes treatments for dogs and cats, saw sales drop 11% from the prior year. Key products such as the dermatology drug Apoquel, the parasiticide Simparica Trio, and the osteoarthritis treatment Librela all experienced weaker demand.
Guidance Lowered
Zoetis revised its full-year 2026 revenue forecast to a range of $9.68 billion to $9.96 billion, down from the previous $9.83 billion to $10.03 billion. Adjusted EPS guidance was cut to $6.85 to $7.00, compared to the earlier $7.00 to $7.10 range. The company now expects total price contribution of just 1% to 2%, down from the prior 2% to 3%, signaling reduced pricing power.
CEO Cites Multiple Headwinds
Chief Executive Kristin Peck described the quarter as more challenging than anticipated, pointing to price-conscious pet owners, a decline in veterinary visits, and reduced spending on premium products. She also noted increased competition in dermatology and parasiticides, two key categories for Zoetis's pet-care business.
Chief Financial Officer Wetteny Joseph was equally blunt, stating on the earnings call that results were "below our expectations this quarter." He highlighted macro headwinds, softer clinic traffic, and competitive pressures as simultaneous challenges. Joseph also flagged a timing shift that pulled approximately $100 million in international sales into Q1 due to a fiscal-year change. Excluding that effect, global organic operational revenue would have declined 5%.
Analyst Reactions
Analysts were quick to downgrade expectations. Daniel Clark at Leerink Partners called U.S. companion-animal sales "well below expectations," attributing the miss to a more price-sensitive market and stiff competition. Stifel analysts calculated that after stripping out the $100 million timing benefit, organic operational revenue growth was 600 to 700 basis points below consensus.
Competitive Landscape Intensifies
Zoetis faces mounting competition from Elanco Animal Health (ELAN), which is launching Zenrelia, a new canine dermatitis drug priced about 20% lower than Zoetis's Apoquel. Elanco is also entering the parasiticide market with Credelio Quattro, directly challenging Simparica Trio.
In response, Zoetis is ramping up direct-to-consumer marketing and increasing its focus on veterinarians. Peck told analysts the company is exploring point-of-sale loyalty programs to help pet owners manage costs at checkout, rather than relying on delayed incentives.
International and Livestock Strength
Not all segments underperformed. International revenue rose 17% as reported, or 10% on an organic operational basis. Livestock sales outside the U.S. climbed 19% reported, 14% organic operational. In the U.S., livestock revenue advanced 7%, supported by demand for cattle, poultry, and swine products.
Outlook and Pipeline
Zoetis management is not anticipating a quick rebound. Joseph said the company is not building any recovery for distributor inventories into its forecast and is preparing for ongoing macro headwinds. The company continues to highlight a pipeline of over a dozen potential blockbuster products—those expected to generate at least $100 million annually—and remains on track to close the Neogen animal genomics acquisition in the second half of 2026.
However, the immediate challenge is clear: U.S. pet-care demand must stabilize before competitors and cautious consumers erode Zoetis's market position further.
